1. Poland Stocks

  2. •

    Consumer non-durables

  3. •

    Household/Personal care
Pharmena S.A.

Pharmena S.A.

GGPW:PHR
2.99
PLN
0.00
(0.00%)
-0.27EPS
35.08MMarket Cap
Pharmena S.A.
GPW:PHR
(Warsaw Stock Exchange)

Recent

price

2.99

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
PLN
1.1
1.06
1.24
1.54
1.53
1.9
1.73
1.42
1.48
1.11
0.9
1.37
1.71
0.11
- -
0.14
0.13
Revenue per Share
0.02
-0.41
-0.56
-0.31
-0.44
-0.39
-0.18
-0.28
-0.05
-0.94
-0.63
-0.41
-0.14
-1.42
- -
-0.25
-0.27
Basic EPS, GAAP
-0.16
-0.26
-0.58
-0.42
-0.64
-0.47
-0.12
0.08
0.41
-1.34
-0.22
-0.32
0.14
2.65
- -
-0.32
-0.31
Free Cash Flow per Basic Share
0.05
0.01
0.04
0.1
0.11
0.11
0.11
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
2.27
1.21
1.22
1.96
1.42
0.94
0.65
0.26
0.22
0.47
-0.01
-0.44
-0.58
2.11
- -
0.87
0.73
Book Value per Share
2.18
0.85
0.93
1.79
1.3
0.86
0.56
0.16
0.08
0.37
-0.1
-0.52
-0.67
2.01
- -
0.74
0.58
Tangible Book Value per Share
7
7
7
9
9
9
9
9
9
10
11
11
11
11
11
11
11
Basic Weighted Avg Shares
8
7
9
14
14
17
16
12
13
11
10
15
19
1
- -
2
1
Sales/Revenue/Turnover
-0.87
-32.49
-33
-9.51
-26.91
-16.27
-7.18
-17.83
0.62
-92.3
-60.76
-26.45
-2.57
-249
- -
-207.42
-227.99
Operating Margin (%)
- -
1
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
- -
- -
- -
- -
Depreciation Expense
- -
-3
-4
-3
-4
-4
-2
-2
- -
-9
-7
-5
-2
-16
- -
-3
-3
Net Income, GAAP
34.78
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
1.61
-39.16
-44.91
-20.11
-28.92
-20.71
-10.46
-19.68
-3.4
-84.96
-69.37
-30.18
-8.25
-1,268.27
- -
-175.59
-209.24
Profit Margin (%)
7
5
6
16
11
7
5
1
- -
2
-3
-3
-7
22
- -
8
6
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
16
8
9
18
13
9
6
2
2
5
- -
-5
-7
23
- -
10
8
Total Equity
-0.27
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
0.77
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
0.77
-23.74
-46.93
-21.04
-26.25
-33.24
-22.77
-58.71
-20.33
-266.65
- -
- -
- -
- -
- -
- -
-31.51
Return on Common Equity (%)

Capital Structure

PLN

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
11
11
11
Market Capitalization
29
37
35

Working Capital

PLN

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
9
8
7
Cash, Cash Equivalents & STI
8
7
6
Accounts Receivable, Net
- -
- -
- -
Inventories
1
1
1
Total Current Liabilities
1
1
1
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

PLN

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

PLN

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
2
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

PLN

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
-0.08
-0.04
- -
- -
2025
-0.04
-0.06
-0.06
-0.08
-0.25
2026
-0.04
-0.09
- -
- -
- -

Quarterly Dividends Per Share

PLN

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Procter & Gamble Company (The) (NYSE:PG)
Cupid Limited (NSE:CUPID)
Hindustan Unilever Limited (NSE:HINDUNILVR)
Colgate-Palmolive (India) Limited (NSE:COLPAL)
Dabur India Limited (NSE:DABUR)
e.l.f. Beauty, Inc. (NYSE:ELF)
Business
Pharmena S.A. Pharmena S.A. (PHR.WA) is a Poland-based biotechnology company that develops, manufactures and commercializes innovative cosmeceuticals, pharmaceuticals and dietary supplements based on its proprietary patented active ingredient 1-MNA (1-methylnicotinamide); core product lines include Dermena for hair loss prevention and treatment, Menavitin dietary supplements targeting cardiovascular health by stimulating prostacyclin production and reducing atherosclerosis risk, Allerco for skin allergies and moderate acne, and Thermi for sunburns, anti-aging, dandruff and body care such as shampoos, conditioners, lotions, tonics and gels. The company operates primarily in Poland with international distribution of active ingredients for medicines and private label production, conducts multidirectional research in dermatology, cardiovascular diseases and lifestyle-related disorders including clinical studies in the United States and Canada, and maintains a diversified portfolio addressing excessive hair loss, skin regeneration, allergies and preventive healthcare. Founded in 2002 and headquartered in Lódz at Gdanska 47/49, Pharmena S.A. focuses on natural physiological solutions protected by over 85 patents in Europe and North America, employs seven people under CEO Konrad Palka, and continues advancing oral medicines for cardiovascular applications while recently emphasizing commercialization of its Menavitin supplement line as a key innovation for elderly consumers to supplement declining natural 1-MNA levels.